SLS SELLAS Life Sciences Group Inc.

-0.23  -20%
Previous Close 1.16
Open 1.14
Price To Book 1.11
Market Cap 21558757
Shares 23,176,475
Volume 1,192,032
Short Ratio
Av. Daily Volume 287,813

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Will meet with FDA in December 2018 to discuss further development path.
NeuVax in combination with Herceptin
Breast cancer - 1+/2+
Phase 3 trial to be initiated late 2017.
Essential Thrombocythemia (ET)
Phase 2 abstract to be presented March 19, 2018.
Multiple Myeloma
Phase 1/2 interim analysis due 4Q 2019.
Galinpepimut-S and Keytruda (pembrolizumab)
Solid tumors
Phase 3 trial planned for 2Q 2019 with interim analysis 3Q 2020.
Acute Myeloid Leukemia (AML)
Phase 1/2 presentation due ASCO June 2018. 1-year PFS rate was 64% in the ITT group.
Galinpepimut-S and nivolumab
Ovarian cancer
Phase 2 completion of enrolment announced November 26, 2018 with data due 4Q 2019.
NeuVax in combination with Herceptin
Breast cancer - HER2 3+

Latest News

  1. SELLAS Life Sciences Reports 2018 Financial Results and Provides Business Update
  2. SELLAS Life Sciences Announces Presentation of Final Data Analysis from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2019 ASCO-SITC Clinical Immuno-Oncology Meeting
  3. Sellas Reviews Strategic Options To Fund Clinical Development Programs
  4. SELLAS Life Sciences Announces Review of Strategic Alternatives
  5. SELLAS Life Sciences Provides Galinpepimut-S and Nelipepimut-S Program Update
  6. SELLAS Life Sciences to Present at the 2019 BIO CEO & Investor Conference
  7. SELLAS Life Sciences Provides Update on Late-Stage Immunotherapy Clinical Development Pipeline
  8. SELLAS to Present Further Correlative Data from Phase 2b Trial of NeuVax + Herceptin® at the 2018 San Antonio Breast Cancer Symposium
  9. SELLAS Life Sciences Announces Expedited Development Path for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Following Feedback from FDA
  10. SELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study of Nelipepimut-S Plus Trastuzumab in High-risk, High-expression HER2 Breast Cancer Patients
  11. SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2018 Financial Results
  12. SELLAS Life Sciences Settles Lawsuit and Prepares to Advance Galinpepimut-S, Analysts Review
  13. Health Care Stocks Making Moves On Friday; Premier Health Group, Inc. (PHGRF) (PHGI), Sellas Life Sciences, Teladoc
  14. SELLAS Life Sciences Announces Additional Data Showing Consistent Clinical Effect Across HLA Allele Subgroups in Triple Negative Breast Cancer (TNBC) Patients Treated with Nelipepimut-S Plus Trastuzumab Presented at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
  15. SELLAS Life Sciences Announces Settlement of Counterclaims Against JGB (Cayman) Newton, Ltd. for $6.6 Million Payment by JGB
  16. SELLAS Life Sciences to Provide Third Quarter 2018 Financial Results and Corporate Update on November 15, 2018
  17. Big Biotech May Be After These Technologies
  18. Today’s Research Reports on Stocks to Watch: Teva Pharmaceutical and SELLAS Life Sciences
  19. 3 Biotechnology & Healthcare Stocks To Watch On Thursday